Skip to main content
Cisplatin has long been considered the standard first-line chemotherapy of choice for cervical cancer patients demonstrating disease recurrence.

Randomized Trial First to Demonstrate a Survival Benefit in Patients with Recurrent Cervical Cancer

Cisplatin has long been considered the standard first-line chemotherapy of choice for cervical cancer patients demonstrating disease recurrence.